In the fight against COVID-19, two FDA-approved mRNA vaccines were developed by Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), which produce the SARS-CoV-2 spike protein to activate potent B and ...

Quantum mechanical modeling allowed the team to develop an initial set of predictions about the role of mutations on infectivity and immune response evasion of Omicron and other SARS-CoV-2 variants ...

Scientists discover that SARS-CoV-2 spike protein remains in the brain and skull bone marrow for years post-infection, causing chronic inflammation and increasing neurodegenerative disease risk.

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

The following is a summary of “Monocytic reactive oxygen species-induced T cell apoptosis impairs cellular immune response to ...

The latest descendant of the Omicron variant of SARS-CoV-2, XEC had arisen through recombination ... by past infections or ...

A new experimental vaccine developed by researchers could offer protection against emerging variants of SARS-CoV-2, as well ...

Newly developed vaccine could protect against emerging SARS-CoV-2 variants and related coronaviruses that may jump from ...

Data showing continued in vitro neutralizing activity of PEMGARDA™ (pemivibart) against XEC have been submitted to the U.S. Food and Drug Administration (FDA), with a timely update to the PEMGARDA ...

Spike. © Emphase/EPFL The use of generative artificial intelligence in protein design stands to revolutionize new drug ...